Cormorant Asset Management, LP Verve Therapeutics, Inc. Transaction History
Cormorant Asset Management, LP
- $1.74 Billion
- Q1 2024
A detailed history of Cormorant Asset Management, LP transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 350,000 shares of VERV stock, worth $1.71 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
350,000
Previous 350,000
-0.0%
Holding current value
$1.71 Million
Previous $4.88 Million
4.73%
% of portfolio
0.27%
Previous 0.29%
Shares
5 transactions
Others Institutions Holding VERV
# of Institutions
170Shares Held
78.3MCall Options Held
125KPut Options Held
185K-
Alphabet Inc. Mountain View, CA12.3MShares$60.3 Million7.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.33MShares$30.9 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.04MShares$29.5 Million0.57% of portfolio
-
Black Rock Inc. New York, NY5.37MShares$26.2 Million0.0% of portfolio
-
State Street Corp Boston, MA5.1MShares$24.9 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $293M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...